SII may begin Novavax vaccine’s clinical trial on children in July

Sources said on Thursday that the Serum Institute of India, the world’s largest manufacturer of vaccines by volume, is planning to launch clinical trials of the Novavax COVID-19 shot for children in July.

Sources added that the Pune-based SII, which is also manufacturing the Oxford-AstraZeneca jab known as Covishield in India, is hoping to introduce the Novavax vaccine, to be known as Covavax in the country, by September.

The development comes just days after Novavax Inc announced that its vaccine had turned out to be more than 90 per cent effective in trials, including against a number of coronavirus variants of concern, in a large, late-stage clinical trial conducted in the United States.

Novavax said the trial was done on nearly 30,000 volunteers in the US and Mexico. According to the company, it is likely to apply for emergency use authorisation in the US and other countries in the third quarter of this year.

As per the study, the vaccine candidate was found to be 93 per cent effective against COVID-19 variants that are more easily transmissible and predominant.

According to Novavax, the vaccine is generally well tolerated. Its side effects seen during the trial include mild headache, fatigue and muscle pain.

According to the company, it is expecting to produce 100 million doses per month by the end of the third quarter of 2021 and 150 million doses per month in the fourth quarter of 2021.


The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies